The short answer
Novo Nordisk submitted CagriSema to the FDA in December 2025, supported by the REDEFINE Phase 3 programme. In its report of 4 November 2026, Novo Nordisk said it expected a US decision in the fourth quarter of 2026; none had been announced by 21 November 2026. It would be the first once-weekly fixed combination of a GLP-1 analogue and an amylin analogue for weight management.
Key facts
- Filed with FDA
- December 2025
- Supporting programme
- REDEFINE Phase 3
- Expected decision
- Q4 2026 (Novo Nordisk, 4 November 2026)
- PDUFA date
- Not publicly confirmed (21 November 2026)
- REDEFINE 1
- 20.4% / 22.7% at 68 weeks
- REDEFINE 2
- 15.7% at 68 weeks (type 2 diabetes)
- REDEFINE 4
- Non-inferiority vs tirzepatide not met
- UK status
- No MHRA authorisation
What has been filed
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, an approved GLP-1 receptor agonist, both administered once weekly. Novo Nordisk submitted it to the FDA in December 2025 for chronic weight management. It would be the first once-weekly combination of GLP-1 and amylin analogues to reach the market.
The evidence supporting it
REDEFINE 1, in adults with obesity and without diabetes, reported 20.4% mean weight reduction at 68 weeks across all randomised participants and 22.7% among those who adhered to treatment, against 3.0% and 2.3% on placebo. REDEFINE 2, in adults with type 2 diabetes, reported 15.7% against 3.1% on placebo. The lower figure in the diabetic population is the expected pattern across the entire incretin class rather than a weakness specific to this combination.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What a filing does and does not mean
Submission opens a review; it does not indicate an outcome. The agency assesses the full dossier including manufacturing and long-term safety, and may request additional data. Company guidance about a decision window is a projection, not a commitment by the regulator. As of 21 November 2026, no PDUFA date had been publicly confirmed by either party and Drugs@FDA listed no product containing cagrilintide.
The UK position
An FDA submission has no bearing on UK availability. CagriSema holds no MHRA authorisation, and any UK approval would follow a separate application and assessment, then a separate NICE appraisal before NHS funding. The gap between those steps is typically a year or more, as the orforglipron timeline illustrates.
How it would sit against what exists
If approved, CagriSema's 20.4% would place it above tirzepatide's head-to-head result against semaglutide but below retatrutide's Phase 3 figures. Retatrutide remains investigational with an FDA filing signalled for the first quarter of 2027, so the competitive picture in 2027 would look different from the one a 2026 approval would enter.
Frequently asked questions
When will CagriSema be approved?
It had not been approved as of 21 November 2026. In its report of 4 November 2026, Novo Nordisk said it expected an FDA decision in the fourth quarter of 2026 and was preparing a US launch in early 2027, subject to approval. No PDUFA date has been made public.
Will it be available in the UK?
Not on the basis of an FDA decision. UK availability requires a separate MHRA authorisation, and NHS funding a separate NICE appraisal after that.
Why does REDEFINE 2 report a lower figure?
It enrolled adults with type 2 diabetes, in whom weight reduction is attenuated across the whole incretin class. Comparisons should be made within population.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefNovo Nordisk files for FDA approval of CagriSemaprnewswire.com
- RefCagriSema REDEFINE 1 results, published in NEJM. Novo Nordiskprnewswire.com
- RefNovo Nordisk submits NDA to FDA for CagriSema. PharmExecpharmexec.com
- RefNovo Nordisk: financial report for the first nine months of 2026, 4 November 2026sec.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- TRIUMPH-5: The Retatrutide vs Tirzepatide Head-to-HeadTRIUMPH-5 randomises 800 adults to retatrutide or tirzepatide over Phase 3. Primary completion is November 2026 - the first direct comparison of the two.
- TRIUMPH-6: Maintenance of Weight ReductionTRIUMPH-6 tests whether reduction is sustained on maintenance dosing. 643 participants, primary completion April 2028 - the field's key question is years away.
- Retatrutide Expanded Access: What It Actually IsA pre-approval expanded access record for retatrutide is listed as available. What expanded access means, who it is for, and what it is emphatically not.
- The Compounded GLP-1 CrackdownThe FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List in April 2026, closing the last legal route for mass compounding.
- MHRA Drug Safety Update: Semaglutide and NAIONOn 5 February 2026 the MHRA warned of a likely association between semaglutide and NAION, a rare optic neuropathy, estimated at up to 1 in 10,000 users.